Part 2/6:
Todd Campbell emphasizes that Soros has been a dynamic player in the biotechnology field, not shying away from the inherent risks associated with investing in biotech stocks. Historically, he has made significant individual bets on biotech companies, leveraging his knowledge and expertise within the industry. However, recent trends suggest a change in his strategy, as he seems to be pivoting toward a more conservative approach.